W W W . Q I A G E N . C O MW W W . Q I A G E N . C O M- 1 -

Bear Stearns19th Annual Healthcare Conference

New York, September 11, 2006

Roland Sackers, CFOCheri Walker, Vice President Merger & Acquisitions NA

W W W . Q I A G E N . C O MW W W . Q I A G E N . C O M- 2 -

Certain of the statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products and markets and operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the DNA sequencing, genomics and synthetic nucleic acid-related markets, as well as the nucleic acid-based molecular diagnostics and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's products (including seasonal fluctuations), difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors, and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that QIAGEN has filed with the U.S. Securities and Exchange Commission (SEC).

The following slides may contain certain summary information about QIAGEN N.V.’s operating income, net income, and earnings per share, which information is presented on a “non-GAAP financial measures”basis rather than in accordance with U.S. generally accepted accounting principles (“GAAP”). Please review QIAGEN’s recent press releases for information on the company’s operating income, net income, and earnings per share for specific periods presented on a GAAP basis. Such GAAP-basis information will also be contained in the company’s reports on Form 20-F and 6-K to be filed with or furnished to the U.S. Securities and Exchange Commission and which are available on QIAGEN’s homepage under www.QIAGEN.com.

Forward Looking Statements

W W W . Q I A G E N . C O MW W W . Q I A G E N . C O M- 3 -

As the innovative market and technology leader, QIAGEN creates indispensable solutions that set standards in enabling access to content from any biological sample.

Our mission is to enable our customers to achieve outstanding success and breakthroughs in research, applied markets, drug development and molecular diagnostics. We thereby make improvements in life possible.

Our commitment to the markets we serve drives our innovation and leadership in all areas where solutions such as sample collection, stabilization, separation, purification, storage, handling and processing are required.

The exceptional talent, skill and passion of our employees are key to QIAGEN’s excellence, success and value.

QIAGEN Mission 2006

MarketLeader

AttractiveMarkets

FocusedPortfolio

W W W . Q I A G E N . C O MW W W . Q I A G E N . C O M- 4 -

Purification of Complex Biological Samples

DNADNASample PrepSample PrepBloodBlood

Nucleolus, Polymerases, Ceramides, Chromosomes,

Chromatin, mRNA, Cytoplasm, Leucocytes, Sugars, Lipids,

Salts, Urea, Carbonic acids, Cofactors, Precursors,

Hemoglobins, Erythrocytes, Monocytes, Smooth

endoplasmatic reticulum, Macrophages, Thrombocytes,

Platelets, Lymphocytes, Basophils, Eosinophils,

Neutrophils, Megacaryocytes, Plasma, Clotting factors,

Actin, Microfilaments, Serum, Fibrin, Lysosomes, Ezrin,

Hemaglobins, Heptaglobins, DNA, Transferrin, Fibrinogen,

Serum albumin, tRNA, Salts, Polymerases, Centrioles,

Immunoglobulins, Carrier proteins, Cytokines,

Angiotensins, Chemokines, Bradykines, Plasma

membranes, Ribosomes, Actin, Vesicles, Complement

components, Nuclei, Rough endoplasmatic reticulum,

Nucleoli, Golgi apparatus, Glycoproteins, Microtubules,

Mitochondria, Mitochondrial nucleic acids, Vacuoles, Talin,

W W W . Q I A G E N . C O MW W W . Q I A G E N . C O M- 5 -

Any content

Enabling Access to the Content of Any Biological Sample

AnyApplication

AnyBiologicalSample

W W W . Q I A G E N . C O MW W W . Q I A G E N . C O M- 6 -

Revenues: 2005: $ 398 million 96–05 CAGR: 25%Net income: 2005: $ 69 million 96–05 CAGR: 33%1

EPS: 2005: $ 0.46 96–05 CAGR: 31%1

Product Range: Approx. 500 consumable products to collect,separate, purify, stabilize, store, amplify target analytes in samples (DNA, RNA, proteins, etc.)

Instrumentation

Molecular diagnostics and research test kits

IP (12/05): 409 issued patents, 321 pending patents

Over 500 patents under license

Customers: >400,000 customers in Academia,Industrial (Pharma/Biotech) and Diagnostics

Employees: >1.800 employees based in 19 subsidiaries

1 excluding acquisition, restructuring and related charges as well as amortization on acquired IP

QIAGEN at a Glance

W W W . Q I A G E N . C O MW W W . Q I A G E N . C O M- 7 -

Academia (approx. 40% of revenues)

Europe strong (esp. Germany)

Asia strong: fast growth in China

Pharma/Biotech (approx. 25% of revenues)

Strong in US and in Europe

Focus on pharma

Focus on biomedical research

Applied testing (approx. 10% of revenues)

Established new channels

Diagnostics (approx. 25% of revenues)

Addressing today’s markets: pathogens

Addressing future opportunities: active in many biomarker

initiatives

Significant accomplishments in building sales channel

Focus on Growth – Momentum

Markets by Customer

AppliedTesting

10%Research40%

Pharma25%

25%

MolecularDiagnostics

W W W . Q I A G E N . C O MW W W . Q I A G E N . C O M- 8 -

QIAGEN: Standards which EnableAccess to the Content of Any Biological Sample

Growth Drivers

0

20.000

40.000

60.000

80.000

100.000

120.000

140.000

160.000

180.000

200.000

220.000

240.000

260.000

280.000

1993 1994 1995 1996 1997 1998 1999 2000 2001

Financials

Intro

W W W . Q I A G E N . C O MW W W . Q I A G E N . C O M- 9 -

QIAGEN: Standards which EnableAccess to the Content of Any Biological Sample

Financials

Growth Drivers

Growth Drivers

0

20.000

40.000

60.000

80.000

100.000

120.000

140.000

160.000

180.000

200.000

220.000

240.000

260.000

280.000

1993 1994 1995 1996 1997 1998 1999 2000 2001

W W W . Q I A G E N . C O MW W W . Q I A G E N . C O M- 10 -

Workflow in Life Sciences

CollectionStabilization

SamplePreparation

Assay Detection

Identical workflows in all areas of Life SciencesApplied Testing

Molecular Diagnostics

Life Science Research

Growth Drivers

W W W . Q I A G E N . C O MW W W . Q I A G E N . C O M- 11 -

Leveraging Core Competencies

Research Applied Testing Molecular Diagnostics

“Prepare Sample”

(Preanalytical Solutions)

“Make Analyte Visible”

(Assay/Test)

“Detect”Open detection platforms

Same core expertise – different markets

“Detect”Open detection platforms

Growth Drivers

W W W . Q I A G E N . C O MW W W . Q I A G E N . C O M- 12 -

Disseminating Technologies Into New Markets

Life ScienceResearch Markets

Applied TestingMarkets

Molecular DiagnosticsMarkets

QIAGEN Sample and Assay Technologies

Common Core Addressing 3 Markets

Growth Drivers

W W W . Q I A G E N . C O MW W W . Q I A G E N . C O M- 13 -

QIAGEN – a Leader in Molecular Diagnostics

Estimated market:> US$ 2 billion (2006)Source: company estimates, various industry research reports

USD Sales inMolecular

Company Diagnostics

Roche 550Genprobe 300Bayer 120QIAGEN 115Digene 115Abbott 110Others

CepheidBiomerieuxBecton DickinsonCelera DxBeckmanInnogeneticsVeridexNanogenThird WaveExactetc.

QIAGEN is a leading player in molecular diagnostics

Source: company estimates, various industry research reports

Viral Infections39%

Non-Viral Infections12%

Genetic Testing13%

Oncology11%

Blood banksOthers25%

!

Growth Drivers

W W W . Q I A G E N . C O MW W W . Q I A G E N . C O M- 14 -

QIAGEN artus Real-time PCR KitsComplete Portfolio for Relevant Infectious Diseases

CMV LC CECMV RG CECMV TM CEHSV 1/2 RG CEHSV 1/2 TM AbbottHHV 6 LC CEHHV 6 RG CEVZV RG CEC. pneumoniae TM CEC. pneumoniae RG CECandida RG CEAspergillus RG CEInfluenza LC CEM. pneumoniae LC CERSV LC CEAdenovirus LC CEB. pertussis LC CEEnterovirus LC CEEnterovirus RG CEEnterovirus TM AbbottL. pneumophila LC CEL. pneumophila RG CEMTB diff LC RUOMTB diff RG RUO

C. pneumoniae LC CEParainfluenza LC CEBorrelia LC CEHAV LC RocheHAV TM AbbottNorovirus LC CEWNV TM ASRInfluenza RG CERSV RG CEAdenovirus RG CEB. pertussis RG CEM. pneumoniae RG CENorovirus RG CEParainfluenza RG CEMTB diff TM CEB. pertussis RG CEC. trachomatis PLUS TM CEC. trachomatis PLUS TM LCC. trachomatis PLUS TM RGHCV LC CEHCV RG CEHIV-1 RNA RG CEGeneral bacteria detectionHHV-6 TM Abbott

L. pneumophila TM AbbottMalaria diff QC LCM. paratuberculosis LC CEM. diff LC CEM. diff TMM. diff RGHemachromatosis LC CEFactor II/V C LC CEDengue RGHTLV LCInfluenza TML. pneumophila TM AbbottMalaria diff QC LCM. paratuberculosis LC CEM. diff LC CEM. diff TMM. diff RGHemachromatosis LC CEFactor II/V C LC CEDengue RGHTLV LCInfluenza TM

Representative but not complete list

Growth Drivers

W W W . Q I A G E N . C O MW W W . Q I A G E N . C O M- 15 -

Molecular Diagnostics Growth Strategy

Multiple, synergistic channels – focused direct sales resources

Direct sales

OEM developmentOEM sales

Direct Sales

Growing direct sales force > 40

No instrument dependency

Focus on pathogens

Market leader is developing countries

OEM Products

Integrated solutions, CE and FDA

Assays, preanalytical, automation

> 15 Partners

>100 clinical trials using QIAGEN

> 50 clinical trials using PreAnalytiX

OEM development

Developing solutions for partners

Growth Drivers

W W W . Q I A G E N . C O MW W W . Q I A G E N . C O M- 16 -

Market leadership in preanalytical solutions

Technology leadership in preanalytical solutions

Expanding leadership in protein sample preparation

Complete portfolio for all markets and segments

Leadership in research markets with PCR and other bioassay technologies

~4th largest molecular diagnostics company

QIAGEN 2006

CollectionStabilization

SamplePreparation

Assay Detection

QIAGEN’s leadership ís growing along the value chain

Growth Drivers

W W W . Q I A G E N . C O MW W W . Q I A G E N . C O M- 17 -

Growth Drivers

0

20.000

40.000

60.000

80.000

100.000

120.000

140.000

160.000

180.000

200.000

220.000

240.000

260.000

280.000

1993 1994 1995 1996 1997 1998 1999 2000 2001

QIAGEN: Standards which EnableAccess to the Content of Any Biological Sample Financials

Financials

W W W . Q I A G E N . C O MW W W . Q I A G E N . C O M- 18 -

200

250

300

350

400

450

500

2001 2002 2003 2004 2005 2006E

QIAGEN Revenue Recognition 2001 – 2006E

5-year CAGR* = 13%

* CAGR 2001-2005

US$ millions

QIAGEN – Continuous double digit revenue growth rates

Financials

W W W . Q I A G E N . C O MW W W . Q I A G E N . C O M- 19 -

QIAGEN Operating Margins 2001 – 2006E

QIAGEN – Strong operating margin improvement

15

17

19

21

23

25

27

29

2001 2002 2003 2004 2005 2006E

% of revenues

26%-28%

Financials

All figures excluding acquisition, integration and relocation related charges as well as amortizationof acquired IP and equity-based compensation (SFAS 123R)

W W W . Q I A G E N . C O MW W W . Q I A G E N . C O M- 20 -

QIAGEN Net Income Recognition 2001 – 2006E

30

40

50

60

70

80

90

2001 2002 2003 2004 2005 2006E

5-year CAGR* = 24%

* CAGR 2001-2005

US$ millions

QIAGEN – Strong earnings engine

US$ 0.46EPS US$ 0.52-US$ 0.56

US$ 0.39US$ 0.32US$ 0.23US$ 0.25

Financials

All figures excluding acquisition, integration and relocation related charges as well as amortizationof acquired IP and equity-based compensation (SFAS 123R)

W W W . Q I A G E N . C O MW W W . Q I A G E N . C O M- 21 -

0.30Cash EPS2

exceeded0.260.23-0.25EPS, adj. (US$)3

high end26%24-26%Operating margin, adj.2exceeded222209-215Net sales

ReportedTarget1In US$ millions unless indicated

QIAGEN well on track to achieve full year guidance

QIAGEN First Six Months 2006 at a Glance

1 based on quarterly guidance communicated by the company on May 9th

2 excluding acquisition, integration and relocation related charges as well as amortization ofacquired IP and equity-based compensation (SFAS 123R)

3 computed using net cash provided by operating activities divided by number of fully diluted shares

Financials

W W W . Q I A G E N . C O MW W W . Q I A G E N . C O M- 22 -

80

90

100

110

120

RevenuesQ2 2005*

Price Volume Newproducts

Acquisitions/Divestments

Exchangerates

RevenuesQ2 2006

0

* Excluding revenues from the divestment of pAllianceand shifted revenues from PAXgene to BD announced in August, 2005

Organic Growth 10%

Divestment related revenuesin Q2 2005 approx. 2% of revenues

~ 2%

~ 4%

~ 4%

~ 13%~ 3%

US$M

New Products and VolumeDriving Organic Growth in Q2

Solid organic growth rate – Comparable to Q1 2006

Financials

W W W . Q I A G E N . C O MW W W . Q I A G E N . C O M- 23 -

ConsumablesReported growth 15%

18% growth CER

Instruments5% growth CERgood growth in BioRobot product lines

Other (1%)

First Six Months 2006 Revenue Distribution

Asia9% of sales24% growth CER(driven by China)

RoW2% of sales

North America45% of sales

10% growth

Europe 44% of sales21% growth CER

90%

9%

CER = Constant exchange rates

Financials

W W W . Q I A G E N . C O MW W W . Q I A G E N . C O M- 24 -

Gross margin driven by increasing high margin consumable business

QIAGEN Margin DevelopmentDriving Profitability

* excluding acquisition, integration and relocation related charges as well as amortization ofacquired IP and equity-based compensation (SFAS 123R)

Gross margin* Operating incomemargin*

Net income margin*

6M 2005

6M 2006 68%70%

26%24%

18%16%

+19%

+20%

+27%

Financials

W W W . Q I A G E N . C O MW W W . Q I A G E N . C O M- 25 -

QIAGEN Guidance

109

101-104

Q1 2006

~18%0.52-0.56Guidance on EPS, adj.in US$ p. share*

~15%453-462121-124115-118Guidance on revenues

May 9, 2006

633Revenue contributionfrom acquisitions

113Actual

~12%439-451118-121112-115108-111Guidance on revenuesFeb 14, 2006

Growth yoy

FY 2006Q4

2006Q3

2006Q2

2006In US$ millionsunless indicated

Guidance for revenues and EPS for FY 2006

* excluding acquisition, integration and restructuring related charges as well as amortization ofacquired IP and equity-based compensation.

Financials

W W W . Q I A G E N . C O MW W W . Q I A G E N . C O M- 26 -

Strong first six months 2006

Exceeded revenue targets

EPS YTD $0.26 (24% growth compared to 2005)

Operating income margin 26% (adj.)

Well on track to achieve full year guidance

Strategic positioning and momentum strong

Molecular Diagnostics

Applied testing

Focused on core competencies

Present in key markets directly (i.e. 2005 Asia expansion)

Strong growth engine

Developed: 39 new products in first six months 2006,approx. 4-5% of sales from new products

Partnered: >50 academic, >50 commercial partnerships

Acquired:

Gentra Systems - an accretive acquisition in Q2

Successful integrations: i.e. artus 12 month scorecard

Executing on Plans – Expanding – Setting Standards

Summary